The fate of Alcon Inc. has long been under consideration by parent company Novartis AG. In early 2018, the Basel, Switzerland-based company said it expected to conduct a spin-off or IPO for its ophthalmic devices business. Now, it has started to detail those plans, committing to a spin-off of the Alcon devices business that's slated to complete during the first half of next year.

The fate of Alcon Inc. has long been under consideration by parent company Novartis AG. In early 2018, the Basel, Switzerland-based company said it expected to conduct a spin-off or IPO for its ophthalmic devices business. Now, it has started to detail those plans, committing to a spin-off of the Alcon devices business that's slated to complete during the first half of next year.

Noninvasive depression device player Neuronetics Inc. has priced an IPO that hits the trinity of positive deal indicators: strong first-day upside, pricing above the anticipated range and increasing the number of shares offered. The Malvern, Pa.-based company saw its shares climb 63 percent on the first day of trading after offering 5.5 million shares, up from the expected 5 million. It priced the offering at $17 per share, above the anticipated range of $14 to $16.

The global conglomerates that dominate medical imaging have all embraced major revamps in recent years. In the latest move, after a year-long review, General Electric Co. has decided to cash out of its GE Healthcare business and make it a standalone company within the next 12 to 18 months.